Over the last decade, therapies targeting immune checkpoints, such as programmed death-
1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response …

Over the last decade, therapies targeting immune checkpoints, such as programmed death-
1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response …

The anticancer activity of immune checkpoint inhibitors is attracting attention in various
clinical sites. Since green tea catechin has cancer-preventive activity in humans, whether …

Abstract Background The PD-L1/PD-1 pathway blockade-mediated immune therapy has
shown promising efficacy in the treatment of multiple cancers including melanoma. The …

Upregulated expression of immune checkpoint molecules correlates with exhausted
phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting …

Abstract PD‐1/PD‐L1 immune checkpoint inhibitors are promising cancer immunotherapies
however responses are still limited and the development of more effective combination …

Many cancer types, including head and neck cancers (HNC), express programmed death
ligand 1 (PD-L1). Interaction between PD-L1 and its receptor, programmed death 1 (PD-1) …

Upregulation of programmed death 1 ligand 1 (PD-L1) in cancer cells and its ligation to PD-
1 on T cells facilitates cancer cell escape from immune surveillance. Therapies with PD-1 or …

Melanoma incidences have increased over the last few decades and metastatic melanoma
is one of the hardest malignancies to treat. Thus, novel approaches are needed for an …

Recently emerging cancer immunotherapies combine the applications of therapeutics to
disrupt the immunosuppressive conditions in tumor-bearing hosts. In this study, we found …